Dynamics of CD133+ cells in cultures of glioma c6 and fetal rat brain under the neurogenic cells supernatant influence

Home/2015, Vol. 3, No. 2/Dynamics of CD133+ cells in cultures of glioma c6 and fetal rat brain under the neurogenic cells supernatant influence

Cell and Organ Transplantology. 2015; 3(2):150-154.
DOI: 10.22494/COT.V3I2.11

Dynamics of CD133+ cells in cultures of glioma c6 and fetal rat brain under the neurogenic cells supernatant influence

Liubich L. D., Lisyany N. I., Semenova V. M., Stayno L. P.
A. P. Romodanov State Institute of Neurosurgery NAMS of Ukraine, Kyiv, Ukraine

Abstract
Cellular and molecular similarities between brain tumor stem cells (BTSCs) and normal neurogenic stem cells (NSCs) motivate the search for new methods of treatment of malignant glioma using NSCs. CD133 molecule could be one of the most typical markers of BTSCs and considered as a target for therapy of brain tumors.
The aim of this study was to evaluate the effect of rat neurogenic cells supernatant (NCsS) on the content of CD133+ cells in glioma C6 cell cultures.
Materials and methods. The cells of rat brain glioma C6 were used as the source for the cultivation; for comparative assessment of tested compound impact on the intact nervous system the fetal rat brain cells on 14th (E14) day of gestation were used. The study was performed in control cultures under standard culture conditions without NCsS adding and tested cultures with adding NCsS (0.10 mg/ml of protein) for 48 hours. NCsS was received from suspensions of rat brain neurogenic cells (E14).
Results. CD133-positive cells were 12.05 ± 4.77 % of the total number of cells in C6 glioma culture and 37.36 ± 12.33 % of the total number of cells in fetal rat brain culture. CD133-positive cells had a smaller size than negative cells (average values of cross-sectional area of cells and nucleus) and greater nuclear-cytoplasmic ratio. The cell and nucleus sizes of CD133-positive cells in cell cultures of fetal rat brain were twice larger than sizes of such cells in cultures of glioma C6.
Under the conditions of NCsS for 48 hours the reducing in the number of CD133-positive cells in rat glioma C6 cell cultures (2.88 ± 0.41 %) and lack of such effects in cell cultures of fetal rat brain (E14) were found.
Conclusion. The morphological differences of CD133-positive cells in glioma C6 cultures and in cell cultures of fetal rat brain (E14) were detected. The decrease of CD133-positive cells in glioma C6 cells culture under the influence of neurogenic cells supernatant was shown.

Key words: glioma C6, fetal rat brain cell culture, neurogenic cells supernatant, CD133

Full Text PDF

1. Angelastro JM, Lame MW. Overexpression of CD133 promotes drug resistance in C6 glioma cells. Mol. Cancer Res. 2010; 8(8):1105–1115.
https://doi.org/10.1158/1541-7786.MCR-09-0383
PMid:20663862 PMCid:PMC2923683
2. Brescia P, Richichi Ch, Pehcci G. Current strategies for identification of glioma stem cells: Adequate or unsatisfactory? J. Oncol. 2012. Available: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366252/pdf/JO2012-376894.pdf.
3. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N. Engl. J. Med. 2005; 353(8):811-822.
https://doi.org/10.1056/NEJMra043666
PMid:16120861
4. Shervington A, Lu C, Shervington A. Expression of multidrug resistance genes in normal and cancer stem cells. Cancer Invest. 2008; 26(5):535-542.
https://doi.org/10.1080/07357900801904140
PMid:18568776
5. Shen G, Shen F, Shi Z, et al. Identification of cancer stem-like cells in C6 glioma cell line and the limitation of current identification methods. In Vitro Cell Dev. Biol. Anim. 2008; 44(7):280-289.
https://doi.org/10.1007/s11626-008-9115-z
PMid:18594936
6. Perez Castillo A, Aguilar-Morante D, Morales-Garcia JA, et al. Cancer stem cells and brain tumors. Clin. Transl. Oncol. 2008; 10(5):262-267.
https://doi.org/10.1007/s12094-008-0195-8
PMid:18490242
7. Mizrak D, Brittan M, Alison MR. CD133 molecule of the moment. J. Pathol. 2008; 214(1):3-9.
https://doi.org/10.1002/path.2283
PMid:18067118
8. Ahmed AU, Ulasov IV, Mercer RW, et al. Maintaining and loading neural stem cells for delivery of oncolytic adenovirus to brain tumors. Methods Mol. Biol. 2012; 797:97-109.
https://doi.org/10.1007/978-1-61779-340-0_8
PMid:21948472
9. Khosh N, Brown CE, Aboody KS, et al. Contact and encirclement of glioma cells in vitro is an intrinsic behavior of a clonal human neural stem cell line. PLoS ONE. 2012; 7(12):e51859. Available: http://www.jourlib.org/paper/3003453.
https://doi.org/10.1371/journal.pone.0051859
PMid:23240066 PMCid:PMC3519902
10. Aboody KS, Najbauer J, Metz MZ, et al. Neural Stem Cell–Mediated Enzyme/Prodrug Therapy for Glioma: Preclinical Studies. Sci. Transl. Med. 2013; 5(184):184-189.
https://doi.org/10.1126/scitranslmed.3005365
PMid:23658244 PMCid:PMC3864887
11. Bovenberg MS, Degeling MH, Tannous BA. Advances in stem cell therapy against gliomas. Trends Mol. Med. 2013; 19(5):281-291.
https://doi.org/10.1016/j.molmed.2013.03.001
PMid:23537753
12. Morshed RA, Gutova M, Juliano J, et al. Analysis of glioblastoma tumor coverage by oncolytic virus-loaded neural stem cells using MRI-based tracking and histological reconstruction. Cancer Gene Therapy. 2015; 22:55–61.
https://doi.org/10.1038/cgt.2014.72
PMid:25525033 PMCid:PMC4293243
13. Stem cell therapeutics for cancer / Shah Kh.(ed.). Wiley Blackwell, 2013. 304 p.
14. Lisyany NI, Liubich LD. Doslidzhennja vplyvu supernatantu nejrogennyh klityn na puhlynoindukujuchu zdatnist’ klityn gliomy 101.8 u shhuriv [Effects of the neurogenic cells supernatant on the tumor-inducing ability of glioma 101.8 in rats]. Klitynna ta organna transplantologija – Cell and Organ Transplantology. 2015; 3(1):52-61.
15. Liubich LD, Semenova VM, Stayno LP. Influence of rat progenitor neurogenic cells supernatant on glioma 101.8 cells in vitro. Biopolymers and Cell. 2015; 31(3):200–208.
https://doi.org/10.7124/bc.0008E1
16. Bozhkova VP, Brezhestovsky PD, Zhuravlev VP, et al. Rukovodstvo po kul’tivirovaniju nervnoj tkani. Metody. Tehnika. Problemy [Guide culturing neural tissue. Methods. Equipment. Problems ] Moskva: Nauka – Moskow: Science, 1988. 317 p.
17. Chen R, Nishimura MC, Bumbaca SM, et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell. 2010; 17(4):362–375.
https://doi.org/10.1016/j.ccr.2009.12.049
PMid:20385361
18. Klassen HJ, Imfeld KL, Kirov II, et al. Expression of cytokines by multipotent neural progenitor cells. Cytokine. 2003; 22(3-4):101-106.
https://doi.org/10.1016/S1043-4666(03)00120-0
19. Liu J, Götherström C, Forsberg M, et al. Human neural stem/progenitor cells derived from embryonic stem cells and fetal nervous system present differences in immunogenicity and immunomodulatory potentials in vitro. Stem Cell Res. 2013; 10(3):325-337.
https://doi.org/10.1016/j.scr.2013.01.001
PMid:23416350
20. Chen HC, Ma HI, Sytwu KH, et al. Neural stem cells secrete factors that promote auditory cell proliferation via a leukemia inhibitory factor signaling pathway. J. Neurosci. Res. 2010; 88(15):3308-3318.
https://doi.org/10.1002/jnr.22492
PMid:20882565
21. Kaminska B, Kocyk M, Kijewska M. TGF beta signaling and its role in glioma pathogenesis. Adv.Exp.Med.Biol. 2013; 986:171-187.
https://doi.org/10.1007/978-94-007-4719-7_9
PMid:22879069
22. Zhang J, Yang W, Zhao D, et al. Correlation between TSP-1, TGF-β and PPAR-γ expression levels and glioma microvascular density. Oncol. Lett. 2014; 7(1):95-100.
PMid:24348828
23. Dubrovska AM, Souchelnytskyi SS. Low-density microarray analysis of TGF1-dependent cell cycle regulation in human breast adenocarcinoma MCG7 cell line. Biopolymers and Cell. 2014; 30(2):107-117.
https://doi.org/10.7124/bc.000888
24. Binder DK, Scharfman HE. Brain-derived Neurotrophic Factor. Growth Factors. 2004; 22(3):123-131.
https://doi.org/10.1080/08977190410001723308
PMid:15518235 PMCid:PMC2504526

Liubich LD, Lisyany NI, Semenova VM, Stayno LP. Dynamics of CD133+ cells in cultures of glioma C6 and fetal rat brain under the neurogenic cells supernatant influence. Cell and Organ Transplantology. 2015; 3(2):150-154. doi: 10.22494/COT.V3I2.11

 

Creative Commons License
Is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.